Currently, a phase 1 trial of KITE-222 (NCT04789408) or other novel Autologous Anti-CLL-1 CAR T-cells is actively enrolling relapsed or refractory AML patients, and the results are awaited. Here, CLEC12A is linked to acute myeloid leukemia.